ReviewFrontiers in microbiology2022
Bacteriophage-Mediated Control of Biofilm: A Promising New Dawn for the Future.
Review in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bacteriophages of Thermophilic 'International journal of molecular sciences · 2024Pooled it
- Escherichia coli bacteriophage vB_EcoS_MS2 effectively prevents biofilm formation but shows limited activity against mature biofilms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- A Lytic Bacteriophage Cocktail Attenuates Carbapenem-Resistant Klebsiella pneumoniae-Acinetobacter baumannii Mixed-Species Biofilms and Reshapes Transcriptional Responses.Microbial biotechnology · 2026Article
- Phages released from Acidithiobacillus ferrooxidans enhance chalcopyrite bioleaching by alleviating passivation and promoting sulfur turnover.Advanced biotechnology · 2026Article
- Isolation, characterization, and genomic analysis of a novel lytic bacteriophage with potent antibiofilm activity against multidrug-resistant Acinetobacter baumannii.BMC microbiology · 2026Article
- Targeting Foodborne Pathogens with Bacteriophages: Mechanisms, Applications, and Resistance.Pathogens (Basel, Switzerland) · 2026Review
- Phage Therapy as an Alternative Strategy Against Pseudomonas aeruginosa: A Narrative Review of Preclinical and Clinical Evidence.MicrobiologyOpen · 2026Review
- Transkingdom Interactions Between Viruses and Bacteria: Implications for Wastewater Treatment Efficiency.Food and environmental virology · 2026Review
- Tackling Biofilm-Forming Pathogens: A Challenge to Overcome in the Fight Against Infectious Diseases.Pathogens (Basel, Switzerland) · 2026Review
- Isolation and Genomic Characterization of a Lytic Bacteriophage Against Multidrug-ResistantViruses · 2026Article
- New Species ofViruses · 2026Article
- Characterization and evaluation of a phage cocktail targeting Salmonella enterica in a Turkey farm.BMC microbiology · 2026Article
- Microbiological and rheological dynamics of mixed biofilms formed by bacteria and eukaryotic virus.Scientific reports · 2026Article
- Prophylactic and therapeutic efficacy of Acinetobacter phage RM_A1 against carbapenem-resistant Acinetobacter baumannii with no cytotoxicity to human skin cells.BMC microbiology · 2026Article
- Phage as control strategy against the foodborne pathogen, Bacillus cereus.Archives of microbiology · 2026Review
- Combination of bacteriophage and antibiofilm compounds from phyllosphere bacteria as a comprehensive strategy for aquaculture and food pathogen control.Scientific reports · 2026Article
- Phage cocktails: state-of-the-art technologies and strategies for effective design.FEMS microbiology reviews · 2026Review
- Anthropogenic Disruption Versus Natural Restoration: Enterobacter cloacae-Driven Barnacle Larval Settlement and Its Mitigation via Natural Bacteriophages.Microbial biotechnology · 2026Article
- Searching for the perfect match: can non-antibiotic antimicrobials improve bacteriophage performance?Frontiers in cellular and infection microbiology · 2026Review
- Bacteriophages targetingFrontiers in microbiology · 2026Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biofilms are complex microbial microcolonies consisting of planktonic and dormant bacteria bound to a surface. The bacterial cells within the biofilm are embedded within the extracellular polymeric substance (EPS) consisting mainly of exopolysaccharides, secreted proteins, lipids, and extracellular DNA. This structural matrix poses a major challenge against common treatment options due to its extensive antibiotic-resistant properties. Because biofilms are so recalcitrant to antibiotics, they pose a unique challenge to patients in a nosocomial setting, mainly linked to lower respiratory, urinary tract, and surgical wound infections as well as the medical devices used during treatment. Another unique property of biofilm is its ability to adhere to both biological and man-made surfaces, allowing growth on human tissues and organs, hospital tools, and medical devices, etc. Based on prior understanding of bacteriophage structure, mechanisms, and its effects on bacteria eradication, leading research has been conducted on the effects of phages and its individual proteins on biofilm and its role in overall biofilm removal while also revealing the obstacles this form of treatment currently have. The expansion in the phage host-species range is one that urges for improvement and is the focus for future studies. This review aims to demonstrate the advantages and challenges of bacteriophage and its components on biofilm removal, as well as potential usage of phage cocktail, combination therapy, and genetically modified phages in a clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.